BACKGROUND: Multiple myeloma (MM) is the second most common hematologic malignancy. Aberrant epigenetic modifications have been reported in MM and could be promising therapeutic targets. As response rates are overall limited but deep responses occur, it is important to identify those patients who could indeed benefit from epigenetic-targeted therapy. METHODS: Since HDACi and DNMTi combination have potential therapeutic value in MM, we aimed to build a GEP-based score that could be useful to design future epigenetic-targeted combination trials. In addition, we investigated the changes in GEP upon HDACi/DNMTi treatment.
INTRODUCTION
Multiple myeloma (MM) is a most often fatal neoplasia characterized by the accumulation of malignant plasma cells (MMCs) in the bone marrow (BM). The profile of DNA methylation in MM comprises genomic global hypomethylation and simultaneous promoter hypermethylation of known or potential tumorsuppressor genes 1, 2 . Recently, hypermethylation of several potential suppressor genes was demonstrated to be associated with significantly shorter overall survival (OS) 1 .
Decitabine (5-aza-2'-deoxycytidine) and 5-azacytidine are both clinically used DNA methyltransferase (DNMT) inhibitors (DNMTi) for the treatment of myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) 3 . In MM, clinical trials are ongoing with DNMTi as monotherapy or combined with lenalidomide or dexamethasone 4 . Histone deacetylases (HDACs) also represent promising molecular targets for the treatment of different cancers, including MM [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Romidepsin and Vorinostat (SAHA) are two HDAC inhibitors (HDACi) that have been approved by the Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma 16 and several pan-HDACi are currently evaluated in clinical trials in MM 4, 14 . Combination of panobinostat/bortezomib/ dexamethasone (PANORAMA) and of vorinostat/bortezomib (VAN-TAGE 088) have been tested in two large phase III clinical trials 17, 18 . Results from the VANTAGE 088 trial showed that the association of vorinostat and bortezomib significantly prolonged progression-free survival (PFS) in patients with relapsed or refractory MM 17 . For the PANORAMA trial, re-evaluation of the results recently showed a significant improvement of the PFS when the pan-HDACi panobinostat was combined with bortezomib and dexamethasone in a prespecified subgroup of patients previously exposed to with both bortezomib and an immunomodulatory agent (IMiD) with relapsed MM resulted in a significant PFS improvement. In addition, the overall response rate was also higher: 59 vs 41%. The FDA and European Medicines Agency pproved panobinostat only very recently in patients who have received at least two prior lines of therapy, including bortezomib and an IMiD [19] [20] [21] . However, this www.nature.com/bjc Table 1 . 22 . HDACi/rhTRAIL or HDACi/ABT-737 combinations are associated with important drug-induced toxicity in vivo. In contrast, HDACi and DNMTi demonstrated a significant reduction of tumor load and prolonged survival of mice without observing major toxicity 22, 23 . In patients with solid cancers or advanced hematological malignancies, HDACi and DNMTi combination was well tolerated 24 and suggested promising activity in MDS, AML 16, 24, 25 , and refractory advanced non-small cell lung cancer 26 . Together, these observations suggest that targeting the aberrant tumorspecific epigenetic program simultaneously with DNMTi and HDACi treatment could have therapeutic interest in MM. However, identification of biomarkers predictive for sensitivity of MMCs to epigenetic therapies remains an important objective to improve clinical trials. We recently reported gene expression (gene expression profiling (GEP))-based risk scores to predict the sensitivity of MMCs to DNMTi 27, 28 and HDACi 28 . Since HDACi and DNMTi combination have potential therapeutic value in MM, we aimed to build a GEP-based score that could be useful to design future epigenetic-targeted combination trials. In addition, we investigated the changes in GEP upon HDACi/DNMTi treatment in High Expression scale
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MATERIALS AND METHODS
Human myeloma cell lines (HMCLs) and primary MM cells of patients HMCLs (N = 40) were obtained as previously described [29] [30] [31] [32] [33] [34] or purchased from DSMZ and American Type Culture Collection. Microarray data are deposited in the ArrayExpress public database (accession numbers E-TABM-937 and E-TABM-1088). Patients presenting with previously untreated MM (N = 206) or monoclonal gammopathy of undetermined significance (MGUS; N = 5) at the university hospitals of Heidelberg and Montpellier, as well as 7 healthy donors have been included in the study approved by the ethics committee of Montpellier and Heidelberg after written informed consent in accordance with the Declaration of Helsinki. Clinical parameters and treatment regimens of the MM patients included in the Heidelberg-Montpellier (HM) cohort were previously described 35 . GEP of purified MMCs was assayed using Affymetrix U133 2.0 plus microarrays (Affymetrix, Santa Clara, CA, USA) as described 36 and data normalized using the MAS5 Affymetrix algorithm. The .CEL and MAS5 files are deposited in the ArrayExpress public database (http://www.ebi.ac.uk/ arrayexpress/), under accession number E-MTAB-362. We also used publicly available MAS5 normalized GEP data (GEO, http:// www.ncbi.nlm.nih.gov/geo/, accession number GSE2658) from purified MMCs of a cohort of 345 patients treated with total therapy 2 protocol (UAMS-TT2 cohort) at the University of Arkansas for Medical Sciences (UAMS, Little Rock, USA) 37 . t(4;14) translocation was evaluated using MMSET spike expression 38 and del17p13 surrogated by TP53 probe set signal 39 for UAMS-TT2 patients. We also used Affymetrix data of 152 relapsed MM patients subsequently treated with bortezomib (GSE9782) from the study of Mulligan et al. 40 Gene expression data of normal memory B cells (MB), preplasmablasts, plasmablasts, and early plasma cells 41, 42 are deposited in the ArrayExpress databases under accession numbers E-MEXP-2360 and E-MEXP-3034.
Identification of genes deregulated by the HDACi/DNMTi combination HMCLs (XG-5, XG-6, XG-7, XG-12, XG-19, XG-20, OPM2, RPMI8226, and LP1) were treated with 0.5 μmol/L decitabine (Sigma, St Louis, MO) for 7 days in RPMI 1640, 10% fetal bovine serum supplemented with interleukin (IL)-6 for IL-6-dependent HMCLs. During the last 24 h, 0.33 μmol/L trichostatin A (TSA; Sigma) was added as described by Heller et al. 43 Whole-genome GEP was assayed with Affymetrix U133 2.0 plus microarrays (Affymetrix). C57BL/KaLwRij mice were purchased from Harlan CPB (Horst, The Netherlands). Mice were housed according to the conditions approved by the Ethical Committee for Animal Experiments of the Vrije Universiteit Brussel (license no. LA1230281). At day 0, naive C57BL/KaLwRij mice were injected with 5 × 10 5 5T33MM cells. After establishment of disease (day 16), mice were treated with the combination of decitabine (0.2 mg/kg) (intraperitoneal injection, daily) and quisinostat (1.5 mg/kg) (subcutaneous injection, once every other day) or vehicle. Compounds were kindly provided by Johnson & Johnson (Beerse, Belgium) and used as a filter-sterilized 10% hydroxypropyl-cyclodextran suspension. After 5 days, mice were sacrified and the bone marrow was isolated from hind legs. For mRNA analysis, tumor cells were purified by depletion of CD11b+ contaminating cells. Cytospins were made before and after depletion to count the percentage of plasma cells as described previously 23 . Samples with >95% plasma cells (N = 4 The prognostic value of Combo score was validated using an independent cohort of 345 patients from UAMS treated with TT2 therapy (UAMS-TT2 cohort). The parameters to compute the Combo score of patients of UAMS-TT2 cohort and the proportions delineating the two prognostic groups were those defined in the HM cohort. c The prognostic value of Combo score was validated in a cohort of 188 patients at relapse treated with bortezomib monotherapy (Mulligan cohort) 40 in each group) were used for RNA isolation using the RNeasy Kit (Qiagen, Venlo, The Netherlands). RNA was further processed and hybridized to the Mouse Genome 430 2.0 Array (Affymetrix, Santa Clara, CA, USA) as previously described 23, 27 . Microarray data are available at ArrayExpress database (Accession number: E-MTAB-3178).
Sensitivity of primary myeloma cells to HDACi/DNMTi combination Primary myeloma cells of 10 patients were cultured with or without graded concentrations of decitabine and TSA. Primary myeloma cells of 15 patients were cultured with or without graded concentrations of 5-azacitidine (Sigma) and vorinostat (SAHA) (Sigma). MMC cytotoxicity was evaluated using anti-CD138-PE monoclonal antibody (mAb; Immunotech, Marseille, France) as described 27, 44 . Results were analyzed using GraphPad Prism (http://www.graphpad.com/scientific-software/prism/).
Statistical analysis
Gene expression data were analyzed using the SAM (Significance Analysis of Microarrays) software 45 as published 38 46 . A histone acetylation/DNA methylation risk score (termed Combo score) was built using our previously published methodology with the decitabine/HDACi combination deregulated prognostic genes 27, 28 . Briefly, the Combo score was constructed as the sum of the Cox model beta coefficients of each of the decitabine/HDACi combination deregulated genes with a prognostic value, weighted by ±1 according to the patient MMC signal above or below the probeset maxstat value 27, 28, 38 . Significantly 49 .
RESULTS

Identification of genes with deregulated expression by decitabine
and HDACi combination and associated with a prognostic value in MM Using gene expression microarrays, we analyzed gene expression changes in HMCLs after ( Supplementary Table S1 ) combination treatment with sub-lethal doses of decitabine and TSA 43 . HDACi/ DNMTi treatment resulted in a significant upregulation of 375 genes (SAM supervised paired analysis, false discovery rate (FDR) < 5%; Supplementary Table S2 ) without significant downregulated genes. Reactome analysis revealed a significant enrichment of genes involved in immunological and inflammatory diseases, p53 and TAp63 anti-oncogenic signaling pathways, and cell-to-cell communication signals (Table 1) . We also used the syngeneic, immunocompetent 5T33MM to study the in vivo transcriptional response of MM cells to HDACi/DNMTi combination as previously described 23 . Similar to the HMCL, the sub-lethal doses showing minimal effects on BM plasmacytosis ensuring the yield of goodquality RNA were used (data not shown). In vivo HDACi/DNMTi treatment resulted in a significant deregulation of 415 genes (SAM supervised paired analysis, FDR < 5%; Supplementary Table S3 ). To identify genes commonly deregulated by the combination in vitro and in vivo, we compared results obtained with the HMCLs and the 5T33MM model. A list of 52 common HDACi/DNMTi deregulated genes was identified ( Supplementary Table S4 ). Using Maxstat R function and Benjamini-Hochberg multiple testing correction 38 , we then investigated the association between the expression levels of these 52 genes and patient prognosis in order to find genes regulated by HDAC and DNMT that could have an important function in MM pathophysiology. Among the 52 genes, 4 genes had a bad prognostic value and 11 a good one in our cohort of 206 newly diagnosed patients (HM cohort) ( Supplementary Table S5 ). The prognostic information of HDACi/ DNMTi combination deregulated genes was gathered in a Combo score as described in the Materials and methods section (Fig. 1a ).
Combo score values in normal, premalignant, or malignant plasma cells are displayed in Fig. 1b . The Combo score value was not significantly different in plasma cells from MGUS patients compared to normal BM plasma cells (BMPCs). However, MMCs of patients have a significantly higher Combo score than plasma cells from MGUS patients (P < 0.001) and HMCLs had the highest score (P < 0.001) ( Fig. 1b) . Investigating the Combo score in the eight groups of the molecular classification of MM, the Combo score was significantly higher in the proliferation and hyperdiploid subgroups (P < 0.001, P = 0.001, and P < 0.001, respectively) and significantly lower in the low bone disease, CD2, and MY subgroups (P = 0.02, P = 0.003, and P = 0.002, respectively) 50 (Supplementary Figure S1 ).
Evaluation of the prognostic significance of the Combo score Using a maxstat analysis for OS 51 , the Combo score was significantly associated with high-risk myeloma in the two independent cohorts of newly diagnosed patients, namely, HM and UAMS-TT2 ( Fig. 2a, b ). Maxstat statistic test split the HM patient cohort into two groups: a high-risk group of 48.6 % patients (Combo score > −6.55) with a 54.9 months median OS and a low-risk group of 51.4% patients (Combo score ≤ −6.55) with not reached median survival (P = 7E−9; Fig. 2a ). In the UAMS-TT2 cohort, a Combo score >−6.55 is also associated with a high risk (P = 0.002; Fig. 2b ) in 47.2% of the patients. Next, we investigated whether the Combo score could also have a prognostic value in relapsed patients. Using the Mulligan cohort, including patients treated with bortezomib monotherapy after relapse, the Combo score kept prognostic value (P = 0.003; Fig. 2c ). The prognostic value of the Combo score was then compared to usual prognostic factors (β2M, ISS, t(4;14), and del17p) and the published GEP-based risk scores, i.e., UAMS-HRS 52 , IFM score 53 , RS score 54 , proliferation scores, GPI 35 , and scores surrogating response to treatment DM score 27 and HA score 28 . In univariate COX analysis, all of these factors had prognostic value (Supplementary Table S5 ). Compared two by two in multivariate COX analysis, Combo score, ISS, IFM score, t(4;14), GPI, DM score, HA score, and β2M remained independent in the HM cohort. In the UAMS-TT2 cohort, when compared two by two, Combo score tested with HRS, IFM score, t(4;14), del17p, RS, GPI, HA score, and DM score remained independent prognostic factors. When tested all together, Combo score, β2M, and RS remained independent in the HM cohort, whereas UAMS-HRS, t(4;14), and del17p were independent in the UAMS-TT2 cohort ( Supplementary Table S6 ).
The Combo score is predictive for myeloma cell sensitivity to DNMTi and HDACi combination The efficacy of the Combo score to predict sensitivity of myeloma cells to DNMTi/HDACi treatment was investigated using primary MMC of patients co-cultured with their bone marrow microenvironment in vitro 27, 28 . MMC of patients with a high Combo score (n = 5) were significantly more sensitive to decitabine and TSA combination than MMC of patients with a low Combo score (n = 5) ( Fig. 3a) . We confirmed these results using another DNMTi and HDACi association. Primary MMCs of patients with a high Combo score (n = 7) exhibited a significant higher sensitivity to the clinical grade inhibitors 5-azacitidine/SAHA combination than MMC of patients with a low Combo score (n = 8) (Fig. 3b ). Altogether, these data indicated that patients with high risk identified using the Combo score could benefit from HDACi/DNMTi treatment.
MMC of patients with a low Combo score value are characterized by a mature BMPC gene signature, whereas patients with high Combo score have a proliferating and MYC-associated gene signatures In order to evaluate whether different gene signatures could be identified comparing the high and low Combo score groups, we performed a gene set enrichment analysis (GSEA). MMC of patients with a low Combo score displayed a significant enrichment in genes associated with normal mature BMPCs (gene set: MOREAUX MULTIPLE MYELOMA BY TACI UP, P < 0.0001, Supplementary Figure S2 and Supplementary Table S7 ) and bone microenvironment dependence (gene sets: KEGG CYTOKINE CYTOKINE RECEPTOR INTERACTION, P < 0.0001, Supplementary  Figure S2 and Supplementary Tables S8). In contrast, MMCs of patients with a high Combo score exhibited a significant enrichment in genes associated with proliferating plasmablastic progenitors (gene sets: WHITFIELD CELL CYCLE S, REACTOME CELL CYCLE P < 0.0001 and P = 0.01, Supplementary Figure S3 and Supplementary Tables S9 and S10) , MYC deregulation (gene sets: ODONNEL TARGETS OF MYC, DANG MYC TARGETS UP, P < 0.0001 and 0.002, Supplementary Figure S3 and Supplementary Table S11 and S12), and transcription (gene set: REACTOME TRANSCRIPTION, P < 0.0001, Supplementary Figure S3 and supplementary Table  S13 ). Investigating the Combo score in normal plasma cell differentiation, the Combo score value was significantly higher in preplasmablasts (PrePB, P = 0.03) compared to MB cells and in plasmablasts (PB, P = 0.04) compared to preplasmablasts (Fig. 4) . Early plasma cells were found to have the highest score (P < 0.001) and the Combo score decreased drastically to the lowest value in mature BMPC (P < 0.001) ( Fig. 4) .
HDACi/DNMTi combination results in significant downregulation of IRF4 and MYC expression
Since MM patients with a high Combo score are characterized by deregulation of MYC target genes, we next investigated the link between DNMTi/HDACi combined treatment and MYC deregulation using nine different HMCLs. Interestingly, GSEA analysis underlined that DNMTi/HDACi treatment results in a significant downregulation of genes silenced by H3K27 and DNA methylation, HDAC, EZH2, IRF4, and MYC target genes, suggesting that the effects of the combination could be mediated by IRF4 and MYC downregulation ( Table 2 ). IRF4 and MYC downregulation after HDACi/DNMTi treatment was validated at the mRNA level by using QPCR (Fig. 5a ) and at the protein level ( Fig. 5b ). Of note, this strong common downregulation of MYC and IRF4 expression was higher compared to DNMTi or HDACi treatment alone (Supplementary Figure S4A -B).
HDACi/DNMTi combination results in epigenetic reprogramming of MMCs As we identified HDACi/DNMTi combined treatment is associated with MYC/IRF4 axis dysregulation thought to play a role in MM pathophysiology, we sought to determine whether HDACi/DNMTi treatment is associated with an epigenetic reprogramming of MMCs. Cluster analysis of the top 100 genes deregulated by HDACi/DNMTi (GSEA analysis) revealed that treated HMCLs cluster with normal BMPC, suggesting that HDACi/DNMTi combined treatment induced a normal BMPC gene program (Fig. 6 ). Altogether, these data indicate an epigenetic reprogramming of MMCs by HDACi/DNMTi combination, associated with MYC/IRF4 axis targeting and normal BMPC gene expression pattern induction.
DISCUSSION
Clinical trials suggested promising activity of HDACi/DNMTi combination in MDS, AML 16, 24, 25 , and refractory advanced nonsmall cell lung cancer 26 . In MM, the oral HDACi panobinostat was recently approved by the US Food and Drug Administration for use in combination with bortezomib and dexamethasone in patients with relapsed MM 19 . In addition, ongoing trials are investigating the therapeutic interest of panobinostat with other agents including next-generation proteasome inhibitors (carfilzomib and ixazomib), IMiD and dexamethasone, bortezomib and IMiD, or monoclonal antibodies in relapsed/refractory MM patients 19 . Moreover, DNMTi and HDACi combination resulted in a significant anti-myeloma activity in the Vk*MYC transgenic MM and 5T33MM mouse models 22, 23 . Importantly, cooperation between histone modifications and DNA methylation is known to be important for the establishment of global epigenetic patterns as well as loci-specific gene regulation 55 In this study, we constructed a GEP-based Combo score that allows identification of high-risk patients associated with MMC's higher sensitivity to HDACi/DNMTi combination in vitro. Since HDACi/DNMTi combination are well tolerated 24 showing promising activity in cancers (including hematological malignancies 16, [24] [25] [26] and have potential therapeutic value in MM 22, 23 , the Combo score could enable the identification of MM patients who could benefit from this treatment.
The 15 genes used to build the Combo score, included 4 genes associated with a bad prognosis and 11 associated with a good prognosis ( Fig. 1 ). Among these genes, some of them could highlight pathways involved in MM biology and sensitivity to DNMTi/HDACi combination. Patients with high Combo score, and poor survival, are characterized by a higher expression of the 4 bad prognostic genes and a lower expression of the 11 good ones in MMCs. Primary MMCs of patients with high Combo score can be efficiently targeted by the upregulation of gene products encoded by genes upregulated by HDACi/DNMTi, in particular the 11 good prognostic genes. A full understanding of the reason why the Combo score could predict for HDACi/DNMTi sensitivity will be provided by an extensive study of the function of the products encoded by HDACi/DNMTi-regulated genes in MMC survival and/ or proliferation. Among them, NFKBIZ was identified. NFKBIZ codes the inhibitor of nuclear factor-κB (NFκB) (IκB) protein IκBζ. IκBζ is an atypical and mainly nuclear IκB protein working as a cotranscription factor of NFκB to modulate the expression of NFκB target genes 57 . NFκB is a major pathway involved in MMC survival and is activated by various gene mutations [58] [59] [60] . NFKBIZ overexpression was reported to induce cell death 61 and inhibit transcriptional activity of STAT3 with Mcl1 downregulation and apoptosis induction 62 . Mcl1 is known to be the major antiapoptotic protein involved in MMC survival 63, 64 . This significant overexpression of NFKBIZ after DNMTi/HDACi treatment was validated by quantitative RT-PCR in seven HMCLs (Supplementary Figure S5 ). As a significant enrichment in genes associated with proliferation was identified in MMC of patients with a high Combo score value, the higher sensitivity of high Combo score patients to DNMTi/HDACi combination could be explained by the fact that incorporation of DNMTi into DNA is restricted to cell cycling cells 3 . Furthermore, HDACi have been shown to induce G1 cell cycle arrest through dephosphorylation of retinoblastoma protein and increase expression of p53 and p21 9, 12, 14 . Using methylationspecific PCR, several studies have identified hypermethylation of tumor-suppressor genes including cyclin-dependent kinase inhibitors (CDKI, p15, and p16) and p14 [65] [66] [67] . DNMTi/HDACi treatment induced p21 and p57 CDKI expression in MMC ( Supplementary  Table S2 ). Thus DNMTi/HDACi combination could be useful to induce the expression of major tumor-suppressor genes in MMC.
Furthermore, core histone proteins must be synthetized rapidly during the brief S-phase when a cell is dividing 68 . As a result, the histone mRNAs are highly cell cycle regulated, increasing 35-fold as cells enter S-phase and decreasing again at the end of Sphase 68 . Altogether, these data could clarify why MMC of high Combo score patients, distinguished by an active growth, can be efficiently targeted by HDACi/DNMTi treatment.
Most interestingly, HDACi/DNMTi treatment induced reprogramming of MMC through IRF4 and MYC axis targeting and induction of a normal BMPC gene expression program. IRF4 is a transcription factor critical for normal plasma cell development 69 . Abnormal activity of IRF4 linked to a translocation or the presence of superenhancers plays a key role in MM development 70, 71 . IRF4 is overexpressed in a subset a patients harboring t(6;14)(p25;q32) translocation 70 . MYC is an IRF4 target presenting prominent role in MM pathogenesis 69 . We report here that HDACi/DNMTi combination triggers a significant downregulation of MYC, IRF4, and several IRF4-MYC target genes. Interestingly, this strong common downregulation of MYC and IRF4 expression was not identified after DNMTi or HDACi treatment alone 27, 28 . It was demonstrated that IMiDs could target IRF4 and MYC expression through binding to cereblon E3 ubiquitin ligase that promote proteasomal degradation of IKZF1 and IKZF3 transcriptional factors 72, 73 .
These data suggest that DNMTi/HDACi could be of therapeutic interest in combination with IMiDs in high-risk MM with elevated Combo score value.
